Is TSHA a good stock to buy? We came across a bullish thesis on Taysha Gene Therapies, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on TSHA. Taysha Gene Therapies, Inc.'s share was trading at $5.36 as of June 9th.
[caption id="attachment_575381" align="aligncenter" width="750"]Taysha Therapeutics (TSHA) is a clinical-stage genetic medicine company focused on developing TSHA-102 for Rett syndrome, and is viewed as a high-conviction opportunity given its regulatory progress, differentiated miRARE...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.